Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A02286-49 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Alcoholic hepatitis carries a risk of high mortality at short term, especially in its severe form. Its diagnosis is confirmed by liver biopsy. The prevalence of alcoholic hepatitis, severe or not severe, is poorly known and prospective data are needed. The present observational study aims to define the prevalence of alcoholic hepatitis among patients admitted for jaundice and determine their outcome according to the severity. Survival and markers of liver dysfunction will be assessed. A biobank including genetic samples will be created to identify the disease profile in terms of inflammation and regeneration. The performance of non-invasive criteria for diagnosis will also be studied.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| cirrhosis | Patients with alcoholic liver disease without alcoholic hepatitis | ||
| severe alcoholic hepatitis | Patients with severe alcoholic hepatitis ( Maddrey score ≥32) | ||
| non-severe alcoholic hepatitis | Patients with non-severe alcoholic hepatitis (Maddrey score <32) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of alcoholic hepatitis in heavy drinkers with jaundice | Assess the prevalence of biopsy-proven alcoholic hepatitis in a cohort of heavy drinkers admitted with recent jaundice | At baseline (time of liver biopsy) |
| Measure | Description | Time Frame |
|---|---|---|
| Survival | Survival rate at 12 months | at 12 months |
| Change in serum total bilirubin | Total bilirubin is a liver parameter, used for the biological liver test evaluation, measured in mg/dl in the serum |
Not provided
Inclusion Criteria:
For SAH group:
Alcohol consumption :
Recent jaundice episode (less than 3 months)
Bilirubin> 50 mg / l (85μmol / l)
For NSAH group:
- Alcohol consumption :
For cirrhosis (control) group:
Alcohol consumption :
Unambiguous presence of cirrhosis criteria, including:
Exclusion Criteria:
For NAH and NSAH groups:
For cirrhosis (control) group:
Not provided
Not provided
Not provided
Patients admitted to jaundice will receive a liver biopsy in accordance with the usual management for diagnosis of alcoholic hepatitis, according to the recommendations of the European Association of Liver Diseases (EASL).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandre Louvet, MD,PhD | Contact | 03 20 44 55 97 | +33 | alexandre.louvet@chru-lille.fr |
| Name | Affiliation | Role |
|---|---|---|
| Alexandre Louvet, MD,PhD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chr Angers | Recruiting | Angers | France | |||
| Chru Besancon |
Not provided
Not provided
Not provided
Not provided
serum, plasma
| Baseline, at 7 days, at 30 days, at 3 months at 6 months and at 12 months |
| Change in serum creatinine | Creatinine is a marker of kidney function, assessed in the blood and measured in milligrams per deciliter | Baseline, at 7 days, at 30 days, at 3 months at 6 months and at 12 months |
| Change in MELD (Model for End-stage Liver Disease)score | The MELD score is a validated tool based on INR, creatinine and bilirubin measured in the blood with the following formula:(9.57 × log creatinine in milligrams per deciliter) + (3.78 × log bilirubin in milligrams per deciliter) + (11.20 × log international normalized ratio) + 6.43. The MELD score is used in liver disorders to assess the degree of liver failure. It has no unit. | Baseline, at 7 days, at 30 days, at 3 months at 6 months and at 12 months |
| Identification of inflammatory and biochemical profiles of patients with severe, non-severe and cirrhotic alcoholic hepatitis, based on the constitution of a biobank (serum and plasma) | Serum and plasma evaluation of translational markers (e.g. cytokines) associated with inflammation in patients with alcohol-related liver disease. The list of markers which will be assessed cannot be determined at present and will depend on other ongoing studies performed in alcoholic hepatitis. | Baseline, at 7 days, at 30 days and at 12 months |
| Identification of the genetic profiles of individuals with severe, non-severe and cirrhotic alcoholic hepatitis( blood sample) | Evaluation of genetic markers associated with alcoholic hepatitis as compared to patients with alcohol-related liver disease without alcoholic hepatitis. We will use a non a priori approach as recommended in genetic studies. Thus, the list of genetic markers cannot be provided at that time. | Baseline |
| Measurement of diagnostic performance (area under the ROC curve) | Measurement of diagnostic performance (area under the ROC curve) of the simple and non-invasive clinical and biological criteria for alcoholic hepatitis proposed in an international expert opinion | At baseline |
| Recruiting |
| Besançon |
| France |
| Hôpital Jean Verdier, AH-HP | Recruiting | Bondy | France |
| Centre Hospitalier Universitaire | Recruiting | Caen | France |
| Hopital Nord - Chu38 - La Tronche | Recruiting | La Tronche | France |
| Hôpital Claude Huriez, CHU | Recruiting | Lille | France |
| Association Hopital Saint Joseph - Marseille | Recruiting | Marseille | France |
| Chu Montpellier | Recruiting | Montpellier | France |
| Hu Est Parisien Site St Antoine Aphp - Paris 12 | Recruiting | Paris | France |
| ID | Term |
|---|---|
| D008108 | Liver Diseases, Alcoholic |
| D006519 | Hepatitis, Alcoholic |
| D008104 | Liver Cirrhosis, Alcoholic |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D020751 | Alcohol-Induced Disorders |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D006505 | Hepatitis |
| D008103 | Liver Cirrhosis |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided